Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
J Nutr Biochem ; 56: 74-80, 2018 06.
Article in English | MEDLINE | ID: mdl-29481986

ABSTRACT

Several studies have demonstrated that fish oil consumption improves metabolic syndrome and comorbidities, as insulin resistance, nonalcoholic fatty liver disease, dyslipidaemia and hypertension induced by high-fat diet ingestion. Previously, we demonstrated that administration of a fructose-rich diet to rats induces liver lipid accumulation, accompanied by a decrease in liver cytosolic lipases activities. In this study, the effect of replacement of soybean oil by fish oil in a high-fructose diet (FRUC, 60% fructose) for 8 weeks on lipid metabolism in liver and epididymal adipose tissue from rats was investigated. The interaction between fish oil and FRUC diet increased glucose tolerance and decreased serum levels of triacylglycerol (TAG), VLDL-TAG secretion and lipid droplet volume of hepatocytes. In addition, the fish oil supplementation increased the liver cytosolic lipases activities, independently of the type of carbohydrate ingested. Our results firmly establish the physiological regulation of liver cytosolic lipases to maintain lipid homeostasis in hepatocytes. In epididymal adipose tissue, the replacement of soybean oil by fish oil in FRUC diet did not change the tissue weight and lipoprotein lipase activity; however, there was increased basal and insulin-stimulated de novo lipogenesis and glucose uptake. Increased cytosolic lipases activities were observed, despite the decreased basal and isoproterenol-stimulated glycerol release to the incubation medium. These findings suggest that fish oil increases the glycerokinase activity and glycerol phosphorylation from endogenous TAG hydrolysis. Our findings are the first to show that the fish oil ingestion increases cytosolic lipases activities in liver and adipose tissue from rats treated with high-carbohydrate diets.


Subject(s)
Adipose Tissue/enzymology , Dietary Carbohydrates/administration & dosage , Fish Oils/administration & dosage , Lipase/metabolism , Liver/enzymology , Soybean Oil/administration & dosage , Adipocytes/enzymology , Animal Feed , Animals , Cytosol/enzymology , Disease Models, Animal , Epididymis/metabolism , Fructose/adverse effects , Glucose Tolerance Test , Hydrolysis , Insulin/chemistry , Lipid Metabolism , Lipogenesis , Lipoprotein Lipase/metabolism , Lipoproteins, VLDL/metabolism , Male , Non-alcoholic Fatty Liver Disease/metabolism , Phosphorylation , Rats , Rats, Wistar , Triglycerides/chemistry , Triglycerides/metabolism
2.
Int J Food Sci Nutr ; 65(4): 489-94, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24456206

ABSTRACT

The aim of the present study was to evaluate the potential of calcium supplementation from Lithothamnium muelleri algae on metabolic and inflammatory parameters in mice with increased adiposity. Male mice were fed and divided during 8 weeks in: control (C), a high refined carbohydrate-containing diet (HC), HC diet supplemented with 1% of Lithothamnion muelleri algae (HC + A) and HC diet supplemented with 0.9% calcium carbonate (HC + C). Animals fed HC diet had increased body weight gain and adiposity, serum glucose and cholesterol, glucose intolerance and decreased insulin sensitivity, compared to control diet. However, the HC + A and HC + C groups did not prevent these aspects and were not able to change the CD14 + cells population in adipose tissue of animals fed HC diet. Calcium supplementation with Lithothamnium muelleri algae and calcium carbonate had no protective effect against the development of adiposity, metabolic and inflammatory alterations induced by HC diet.


Subject(s)
Adiposity , Anti-Obesity Agents/therapeutic use , Calcium, Dietary/therapeutic use , Complex Mixtures/therapeutic use , Dietary Supplements , Obesity/prevention & control , Rhodophyta/chemistry , Adipose Tissue, White/blood supply , Adipose Tissue, White/immunology , Adipose Tissue, White/pathology , Animals , Anti-Inflammatory Agents, Non-Steroidal/analysis , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Anti-Inflammatory Agents, Non-Steroidal/isolation & purification , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Anti-Obesity Agents/analysis , Anti-Obesity Agents/chemistry , Anti-Obesity Agents/isolation & purification , Blood Vessels/immunology , Blood Vessels/pathology , Calcium Carbonate/administration & dosage , Calcium Carbonate/analysis , Calcium Carbonate/isolation & purification , Calcium, Dietary/analysis , Calcium, Dietary/isolation & purification , Cells, Cultured , Complex Mixtures/chemistry , Dietary Carbohydrates/adverse effects , Dietary Supplements/analysis , Food Handling , Glucose Intolerance/etiology , Glucose Intolerance/prevention & control , Insulin Resistance , Macrophages/immunology , Macrophages/pathology , Male , Mice , Obesity/etiology , Obesity/immunology , Obesity/physiopathology , Stromal Cells/immunology , Stromal Cells/pathology , Weight Gain
3.
Life Sci ; 90(13-14): 476-83, 2012 Apr 09.
Article in English | MEDLINE | ID: mdl-22285839

ABSTRACT

AIMS: As cardiac performance is closely related to its energy supply, our study investigated the effect of the orotic acid cardioprotective agent on the pathways of energy supply, in both conditions of normal flow and ischemia. MAIN METHODS: Male Wistar rats were fed during nine days with a balanced diet only or supplemented with 1% orotic acid. KEY FINDINGS: Dietary administration of orotic acid increased the cardiac utilization of fatty acids, activity of the lipoprotein lipase, expression of the gene of peroxisome proliferator-activated receptor α and its target enzymes. In addition, orotic acid increased the myocardial uptake and incorporation of glucose, glycogen content and level of GLUT4, concentration of glycolytic metabolites and lactate production in both experimental conditions, baseline and after regional ischemia. SIGNIFICANCE: Thus, in orotic acid hearts there was a simultaneous stimulus of fatty acid oxidation and glycolytic pathway, reflected in increased energetic content even in pre-ischemia. The analysis of the cardiac contractility index showed a positive inotropic effect of orotic acid due, at least in part, to the increased availability of energy. The result allows us to suggest that the metabolic changes induced by orotic acid result in appreciable alterations on myocardial contractile function.


Subject(s)
Diet , Energy Metabolism/drug effects , Heart/drug effects , Heart/physiology , Myocardial Contraction/drug effects , Myocardial Ischemia/physiopathology , Myocardium/metabolism , Orotic Acid/pharmacology , Animals , Fatty Acids/metabolism , Glycolysis/drug effects , Humans , Lipoprotein Lipase/metabolism , Male , Orotic Acid/administration & dosage , Oxidation-Reduction , Rats , Rats, Wistar
4.
Life Sci ; 82(15-16): 876-83, 2008 Apr 09.
Article in English | MEDLINE | ID: mdl-18374364

ABSTRACT

The experiments performed in this report were designed to investigate the mechanisms involved in the metabolic alterations associated with orotic acid-induced hepatic steatosis and the effect of fenofibrate, a stimulant of peroxisome proliferators-activated receptor alpha (PPARalpha), on these alterations. Male Wistar rats were divided into three experimental groups: 1) fed a balanced diet (C); 2) fed a balanced diet supplemented with 1% orotic acid (OA); 3) fed OA diet containing 100 mg.kg(-1) bw.day(-1) fenofibrate (OA+F), for 9 days. Administration of OA to rats induced significant increase in the hepatic total lipids content, marked microvesicular steatosis and decrease in plasma lipids concentrations compared to control group. Fenofibrate treatment prevented fatty liver induction, caused an additional reduction on plasma lipids concentrations and caused a 40% decrease in the lipogenic rate in adipose tissue. The results also showed a 40% increase in lipoprotein lipase (LPL) activity in adipose tissue from OA treated group and fenofibrate administration induced a 50% decrease in LPL activity. The liver mRNA expression of PPARalpha and ACO (acyl CoA oxidase) were 85% and 68% decreased in OA group when compared to control, respectively. Fenofibrate treatment increased the PPARalpha and ACO expressions whereas the CPT-1 (carnitine palmitoyl transferase-1) expression was not altered. Our results have shown that fenofibrate treatment decreases the hepatic lipid content induced by OA which is mediated by an important increase in fatty acid oxidation consequent to an increase in hepatic mRNA expression of PPARalpha and ACO.


Subject(s)
Fenofibrate/therapeutic use , Hepatic Insufficiency/chemically induced , Hepatic Insufficiency/prevention & control , Hypolipidemic Agents/therapeutic use , Orotic Acid/antagonists & inhibitors , Orotic Acid/toxicity , Acyl-CoA Oxidase/biosynthesis , Adipocytes/drug effects , Adipocytes/metabolism , Adrenergic beta-Agonists/pharmacology , Animals , Cell Separation , Diet , Hepatic Insufficiency/pathology , Hypoglycemic Agents/pharmacology , Insulin/pharmacology , Isoproterenol/pharmacology , Lipid Metabolism/drug effects , Lipids/biosynthesis , Lipolysis/drug effects , Lipoprotein Lipase/metabolism , Liver/pathology , Male , PPAR alpha/biosynthesis , Rats , Rats, Wistar , Reverse Transcriptase Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL